{"gene":"TARDBP","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":2021,"finding":"Cryo-EM structural determination of pathological TDP-43 filaments from ALS with FTLD brain revealed an amyloid-like filament comprising a single protofilament with a double-spiral-shaped fold spanning residues 282-360 in the low-complexity domain, showing no similarity to TDP-43 filaments formed in vitro and lacking classical cross-β amyloid structure.","method":"Cryo-electron microscopy of brain-derived TDP-43 aggregates","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution cryo-EM structure from two independent individuals and two brain regions, replicated within the same study","pmids":["34880495"],"is_preprint":false},{"year":2019,"finding":"RNA binding antagonizes neurotoxic phase transitions of TDP-43: aberrant interactions between low-complexity domains drive pathological inclusion formation, and this process is antagonized by RNA binding. Pathological inclusions can form outside stress granules. Treatment with oligonucleotides composed of TDP-43 target sequences prevents inclusions and rescues neurotoxicity.","method":"Optogenetic induction of TDP-43 proteinopathy in live cells with spatiotemporal control, live-cell imaging, neurotoxicity assays","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (optogenetics, live imaging, oligonucleotide rescue), mechanistically validated in live neurons with functional readout","pmids":["30826182"],"is_preprint":false},{"year":2016,"finding":"TDP-43 accumulates in neuronal mitochondria in ALS/FTD. In mitochondria, wild-type and mutant TDP-43 preferentially bind mitochondria-transcribed mRNAs encoding respiratory complex I subunits ND3 and ND6, impairing their expression and causing specific complex I disassembly. Suppression of TDP-43 mitochondrial localization abolishes mitochondrial dysfunction and neuronal loss, and improves phenotypes in transgenic mutant TDP-43 mice.","method":"Mitochondrial fractionation, RNA immunoprecipitation, respiratory complex activity assays, transgenic mouse studies with TDP-43 mitochondrial localization signal blocking","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (fractionation, RIP, functional complex assays, in vivo rescue), replicated across cell and mouse models","pmids":["27348499"],"is_preprint":false},{"year":2020,"finding":"HSP70 family chaperones are the primary components of the liquid core of TDP-43 'anisosomes' (intranuclear liquid spherical shells formed by RNA binding-deficient TDP-43). ATP-dependent HSP70 activity maintains the liquidity of both shells and cores. Reduction of ATP levels converts anisosomes to solid aggregates. Acetylation of RNA recognition motifs renders TDP-43 unable to bind RNA, driving anisosomes formation.","method":"Live-cell imaging, cryo-electron tomography, mathematical modeling, proteomics (mass spectrometry of anisosomes components), ATP depletion experiments, proteasome inhibition in neurons","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural imaging plus proteomic identification of HSP70 as core component, functional validation with ATP manipulation and mutagenesis","pmids":["33335017"],"is_preprint":false},{"year":2021,"finding":"TDP-43 condensation capacity (governed by C-terminal domain) is required for efficient assembly on subsets of RNA-binding regions containing long clusters of UG-rich motifs, promoting 'binding-region condensates' via homomeric CTD interactions, and is necessary for regulation of a subset of bound transcripts including TDP-43 mRNA autoregulation.","method":"Series of TDP-43 CTD variants with graded condensation propensity; in vitro phase separation assays; nuclear mobility (FRAP); iCLIP for RNA-binding regions; RNA-seq for transcriptome regulation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution in vitro combined with iCLIP and RNA-seq, multiple CTD variants, orthogonal functional readouts in single study","pmids":["34380047"],"is_preprint":false},{"year":2022,"finding":"Casein kinase 1δ-mediated TDP-43 hyperphosphorylation on C-terminal serine residues reduces TDP-43 phase separation and aggregation, rendering condensates more liquid-like and dynamic. Phosphomimetic mutations do not affect nuclear import or RNA regulatory functions but suppress accumulation in membrane-less organelles. Multi-scale molecular dynamics simulations reveal reduced homotypic interactions through enhanced solvation of phosphomimetic residues.","method":"In vitro phase separation assays with phosphomimetic TDP-43 variants; CK1δ kinase assays; FRAP; molecular dynamics simulations; cellular localization and RNA splicing assays","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution of kinase activity, phosphomimetic mutagenesis, molecular simulation, and cellular functional assays in single study","pmids":["35112738"],"is_preprint":false},{"year":2025,"finding":"TDP-43 aggregation requires two concurrent events: up-concentration within stress granules beyond a threshold AND oxidative stress. These collectively trigger intra-condensate demixing via RRM1 domain unfolding (enabling intermolecular disulfide bonds) and increased hydrophobic patch interactions in the C-terminal domain, generating a TDP-43-enriched phase within stress granules that transitions to pathological aggregates. TDP-43 variants resistant to intra-condensate demixing eliminate pathological aggregates.","method":"Live-cell imaging, optogenetic concentration control, iPS-motor neurons, disease mouse model validation, patient sample analysis, engineered TDP-43 variants resistant to demixing","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mechanistic validation using engineered variants, multiple model systems including patient samples, and in vitro reconstitution components; single lab but multiple orthogonal methods","pmids":["40412392"],"is_preprint":false},{"year":2023,"finding":"TDP-43 oligomerization and RNA binding govern TDP-43 stability, splicing functionality, LLPS, and subcellular localization. Oligomerization is modulated by RNA binding. Under impaired proteasomal activity: monomeric TDP-43 forms cytoplasmic inclusions via aggresome-dependent pathway, while RNA binding-deficient TDP-43 aggregates in the nucleus via LLPS-driven pathway.","method":"Structure-based TDP-43 variants in human neurons and cell lines; near-physiological expression; proteasome inhibition; co-immunoprecipitation; FRAP; imaging","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — structure-based mutations, human neurons, near-physiological expression, multiple orthogonal methods dissecting distinct aggregation pathways","pmids":["37431963"],"is_preprint":false},{"year":2023,"finding":"Seeding of TDP-43 aggregation requires post-fibrillization proteolytic cleavage to expose the β-sheet-rich amyloid core buried by flanking structured domains in full-length TDP-43 filaments. Only TDP-43 filaments with exposed amyloid core efficiently seeded aggregation of endogenous TDP-43 in cells and enhanced seeding by brain-derived TDP-43 aggregates.","method":"Recombinant full-length TDP-43 filament production; structural characterization; proteolytic cleavage assays; cell-based seeding assays with brain-derived aggregates","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of fibrils, structural characterization, functional seeding assays with brain-derived material; single lab but multiple orthogonal methods","pmids":["37248338"],"is_preprint":false},{"year":2019,"finding":"Loss of nuclear TDP-43 is associated with chromatin decondensation around long interspersed nuclear elements (LINEs) and increased LINE1 DNA content. Loss of TDP-43 leads to increased retrotransposition that can be inhibited with antiretroviral drugs.","method":"Subcellular fractionation, FACS enrichment of TDP-43-negative nuclei from post-mortem FTD-ALS brain, RNA-seq, ATAC-seq for chromatin accessibility, LINE1 retrotransposition assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Moderate — primary human tissue combined with functional retrotransposition assay and chromatin accessibility profiling; multiple orthogonal methods","pmids":["31042469"],"is_preprint":false},{"year":2017,"finding":"TDP-43 suppresses tau expression by promoting mRNA instability through binding to UG repeats in the 3'-UTR of tau mRNA. The C-terminal region of TDP-43 is required for this function. ALS-causing TDP-43 mutations differentially affect tau mRNA instability.","method":"mRNA stability assays (actinomycin D chase), RNA immunoprecipitation, TDP-43 truncation mutants, in vivo TDP-43(M337V) transgenic mouse analysis, human brain correlation studies","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — RIP identifying 3'UTR binding, mRNA stability assays, domain mapping, in vivo validation in transgenic mice and human brain; multiple methods across labs","pmids":["28335005"],"is_preprint":false},{"year":2021,"finding":"TDP-43 is SUMOylated in the nuclear compartment both covalently (at lysine 136 via SUMO E3 ligase PIAS4, confirmed by SUMO-mutant K136R) and non-covalently in the RRM1 domain at a SUMO-interacting motif (residues 106-110). SUMOylation modifies TDP-43 splicing activity (specifically exon skipping), influences subcellular localization, and regulates recruitment to stress granules after oxidative stress. DeSUMOylation by SENP1 increases cytoplasmic TDP-43 localization.","method":"Co-immunoprecipitation of SUMO-TDP-43, site-directed mutagenesis (K136R), SENP1 overexpression, cell-permeable SENP1 peptide TS-1, splicing assays, immunofluorescence","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP and mutagenesis identifying SUMOylation site, functional splicing assay, single lab with multiple methods","pmids":["34390468"],"is_preprint":false},{"year":2021,"finding":"O-GlcNAc transferase (OGT)-mediated O-GlcNAcylation of TDP-43 suppresses TDP-43 aggregation and hyperphosphorylation and promotes TDP-43's mRNA splicing function. O-GlcNAcylation of TDP-43 promotes proper splicing of STMN2 mRNA, required for normal axonal outgrowth and regeneration.","method":"Biochemical O-GlcNAcylation assays, OGT inhibition/overexpression, splicing assays, Drosophila motor neuron overexpression with locomotion and lifespan readouts","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro biochemical assay plus in vivo Drosophila validation, multiple functional readouts; single lab","pmids":["33855783"],"is_preprint":false},{"year":2019,"finding":"TDP-43 in pluripotent cells represses formation of paraspeckles by enhancing the polyadenylated short isoform of Neat1 lncRNA. TDP-43 promotes pluripotency by regulating alternative polyadenylation of transcripts encoding pluripotency factors including Sox2, partially protecting its 3'UTR from miR-21-mediated degradation. Conversely, paraspeckles sequester TDP-43 from mRNAs to promote exit from pluripotency.","method":"RNA-seq, TDP-43 knockdown/overexpression in mouse embryonic stem cells, alternative polyadenylation analysis, miRNA reporter assays, mouse embryo patterning phenotypes","journal":"Molecular cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic experiments (RNA-seq, polyadenylation assays, miRNA reporters, in vivo embryo phenotypes) in single study; single lab","pmids":["31047794"],"is_preprint":false},{"year":2020,"finding":"C9orf72-derived poly(GR) protein promotes aggregation of endogenous TDP-43 by mediating sequestration of full-length TDP-43 in an RNA-independent manner, inducing cytoplasmic TDP-43 inclusion formation. Poly(GR) also causes mislocalization of nucleocytoplasmic transport factors and nuclear pore complex proteins, resulting in aberrant cytoplasmic accumulation of TDP-43.","method":"GFP-(GR)200 transgenic mouse model; immunofluorescence; co-immunoprecipitation; antisense oligonucleotide treatment; RNase treatment to confirm RNA-independence","journal":"Science translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic mouse model, RNase treatment establishing RNA-independence, ASO rescue; single lab with multiple methods","pmids":["32878979"],"is_preprint":false},{"year":2019,"finding":"TDP-43 knockdown in astrocytes causes accumulation of repetitive element transcripts (including endogenous retroviral sequences) and double-stranded RNA (dsRNA), which activates innate immune signaling through protein kinase R (PKR). Inhibition or knockdown of PKR blocks the pro-inflammatory response induced by TDP-43 loss.","method":"siRNA knockdown of TDP-43 in primary rat astrocytes, RNA-seq, immunofluorescence, immunoblotting, PKR chemical inhibition and siRNA knockdown","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function KD with defined molecular mechanism (dsRNA-PKR axis), PKR epistasis rescue; single lab","pmids":["31229690"],"is_preprint":false},{"year":2017,"finding":"TDP-43 regulates cryptic exon inclusion in a cell-type-specific manner. Conditional deletion of TDP-43 in excitatory neurons or skeletal myocytes revealed that the majority of TDP-43-repressed cryptic exons are cell type-specific, with only some shared across stem cells, neurons, and myocytes.","method":"Conditional knockout mouse models (excitatory neurons and skeletal myocytes), RNA-seq identification of cryptic exons","journal":"Molecular neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic deletion with transcriptomics readout; single lab but clean conditional KO","pmids":["28153034"],"is_preprint":false},{"year":2022,"finding":"Stage-specific genetic inactivation of Tardbp in oligodendrocyte lineage cells showed that OPCs require TDP-43 for survival (deletion causes cell loss and rapid regeneration), while oligodendrocytes become less sensitive as they mature. TDP-43 loss in oligodendrocytes causes missplicing of key myelination proteins (cryptic exon incorporation) and morphological defects including inappropriate wrapping of neuronal somata and blood vessels.","method":"Conditional in vivo Cre-lox deletion at specific oligodendrocyte lineage stages; transcriptional analysis; behavioral phenotyping; electron microscopy","journal":"eLife","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean stage-specific genetic inactivation with defined cellular and molecular phenotypes; single lab but multiple lineage stages examined","pmids":["35311646"],"is_preprint":false},{"year":2021,"finding":"DCTN1 binds TDP-43 through its CAP-Gly-basic supradomain, dynactin domain, and C-terminal region, preferentially via TDP-43's C-terminal region. The Perry disease-linked DCTN1 p.G71A mutation impairs this interaction. Overexpression of DCTN1(G71A), the dynactin-domain fragment, or C-terminal fragment induces cytoplasmic mislocalization and aggregation of TDP-43.","method":"Co-immunoprecipitation, truncation mutant mapping, overexpression of disease mutant DCTN1, immunofluorescence for TDP-43 localization","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — reciprocal domain-mapping pulldown and functional mislocalization assay; single lab, multiple truncation constructs","pmids":["33924373"],"is_preprint":false},{"year":2019,"finding":"TDP-43 turnover and toxicity depend in part upon the endocytosis pathway. TDP-43 inhibits endocytosis and co-localizes with endocytic proteins. Impairing endocytosis increases TDP-43 toxicity, aggregation, and protein levels, while enhancing endocytosis reverses these phenotypes. Locomotor dysfunction in a TDP-43 ALS fly model is exacerbated by endocytic impairment and suppressed by enhancement of endocytic function.","method":"Yeast genetics, Drosophila ALS model, co-localization with endocytic markers in ALS patient tissue, endocytosis modulation assays, protein level measurements","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in yeast and Drosophila with patient tissue co-localization validation; single lab but multiple model systems","pmids":["29233983"],"is_preprint":false},{"year":2020,"finding":"Cdc48 (VCP in mammals) physically interacts and co-localizes with TDP-43 in ALS patient tissue, and regulates TDP-43 turnover and toxicity together with its cofactor Ubx3 (implicated in endocytic function) in yeast. TDP-43 expression impairs endocytic function.","method":"Yeast genetic screen, co-immunoprecipitation in yeast and ALS patient tissue, toxicity and protein turnover assays, endocytic function measurements","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast genetics plus patient tissue co-IP validation; single lab","pmids":["31767634"],"is_preprint":false},{"year":2019,"finding":"TARDBP overexpression induces impairment of the ubiquitin proteasome system (UPS). PTK2/FAK is a suppressor of neurotoxicity induced by UPS impairment downstream of TDP-43. PTK2 activation promotes phosphorylation of SQSTM1/p62 at S403 via TBK1, impairing autophagic degradation of poly-ubiquitinated proteins. Non-phosphorylatable SQSTM1(S403A) reduces insoluble poly-ubiquitinated proteins and neurotoxicity caused by TDP-43 overexpression.","method":"Kinase inhibitor screen, Drosophila genetic model, site-directed mutagenesis (SQSTM1 S403A), co-immunoprecipitation, proteasome activity assays, TBK1 epistasis","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase screen, pathway epistasis (PTK2-TBK1-SQSTM1), phospho-null mutant rescue in cells and Drosophila; single lab","pmids":["31690171"],"is_preprint":false},{"year":2021,"finding":"CHMP2B regulates TDP-43 phosphorylation and toxicity independent of autophagy via CK1. Downregulation of CHMP2B reduces TDP-43 phosphorylation and toxicity in Drosophila and mammalian cells. CHMP2B modulates CK1 protein levels by negatively regulating ubiquitination and proteasome-mediated turnover of CK1.","method":"Drosophila genetic screen, siRNA knockdown in mammalian cells, CK1 inhibition, ubiquitination assays, proteasome assays, immunoblotting","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in Drosophila, mechanism dissected in mammalian cells with kinase inhibition and ubiquitination assays; single lab","pmids":["34726688"],"is_preprint":false},{"year":2019,"finding":"TDP-43 broadly affects transcription of protein-coding genes and Alu retrotransposons genome-wide. Loss of TDP-43 results in increased transcription activity near repetitive Alu elements within expressed genes, with the highest densities in shorter genes (<30 kb) whose transcription is most affected by TDP-43.","method":"GRO-seq (global run-on sequencing), TDP-43 knockdown in HEK293T cells, ChIP for TDP-43 at transcribed regions","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genome-wide nascent transcription assay with TDP-43 KD; single lab, mechanistically informative readout","pmids":["31655156"],"is_preprint":false},{"year":2023,"finding":"HSP70 and HSP90 chaperones promote TDP-43 phase separation, while HSP40 co-chaperones (DNAJA2, DNAJB1, DNAJB4, DNAJC7) show distinct effects on TDP-43 de-mixing. Chaperones and co-chaperones primarily recognize structured helical elements in TDP-43's prion-like domain. Methionine sulfoxidation of the second helical element impairs phase separation, amyloid formation, chaperone recognition, and alters phosphorylation by CK1δ.","method":"NMR structural characterization of TDP-43 prion-like domain, in vitro phase separation assays with purified chaperones, methionine sulfoxidation, kinase phosphorylation assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — NMR structural data with in vitro biochemical reconstitution of chaperone effects; single lab but multiple orthogonal methods","pmids":["36709343"],"is_preprint":false},{"year":2021,"finding":"Cytoplasmic TDP-43 associates with polyribosomes in an SH-SY5Y cellular stress model and is detected on polyribosomes in FTD brain lysate, supporting a role for cytoplasmic TDP-43 in translational control during stress. Sorbitol-driven cytoplasmic TDP-43 accumulation followed by oxidative stress triggers PARP cleavage and cellular toxicity.","method":"Polyribosome fractionation, immunofluorescence, PARP cleavage assays, brain lysate analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — polyribosome fractionation in cells and patient brain tissue with functional toxicity readout; single lab","pmids":["34378050"],"is_preprint":false},{"year":2022,"finding":"TDP-43 oligomerization and phase separation properties are both essential for TDP-43 autoregulation (negative feedback via binding to its own 3'UTR). RNA binding to the central autoregulatory 3'UTR sequence induces TDP-43 condensation in cell lysates. ALS-associated mutation M337V disrupts liquid properties of TDP-43-RNA condensates and autoregulatory function, and decreases cellular clearance of TDP-43.","method":"Phase separation assays with purified TDP-43 variants, cell lysate condensation assays, autoregulatory reporter assays, FRAP, fluorescence anisotropy binding assays","journal":"Frontiers in neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phase separation and binding assays combined with cellular autoregulation reporter; single lab","pmids":["35495061"],"is_preprint":false},{"year":2025,"finding":"During oxidative stress, TDP-43 is SUMO2/3-ylated by the SUMO E3 ligase PIAS4 within stress granules. Inhibition of TDP-43 SUMO2/3-ylation or PIAS4 depletion leads to irreversible TDP-43 aggregation in stress granules. Binding of TDP-43 to UG-rich RNA antagonizes PIAS4-mediated SUMO2/3-ylation, while RNA dissociation promotes it. SUMO2/3-ylation stabilizes cytosolic RNA-free TDP-43 against aggregation.","method":"SUMO conjugation assays, PIAS4 knockdown/inhibition, stress granule assembly assays, RNA binding mutants, immunofluorescence, biochemical aggregation assays","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — identification of specific E3 ligase (PIAS4) with functional consequence, RNA-SUMO antagonism demonstrated; single lab, multiple methods","pmids":["39982984"],"is_preprint":false},{"year":2024,"finding":"TDP-43 loss of function induces cryptic alternative polyadenylation (APA) events including alternative last exons (ALE), 3'UTR extensions, and intronic polyadenylation. TDP-43 can have both repressive and enhancing action on APA. Cryptic 3'UTR extensions in transcription factors (e.g., ELK1, SIX3, TLX1) lead to increased RNA stability, higher cytoplasmic localisation, and increased wild-type protein translation.","method":"Custom bioinformatic APA pipeline, RNA-seq and Ribo-seq, TDP-43 depletion in cells, post-mortem ALS/FTD brain RNA-seq validation","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Ribo-seq and RNA-seq orthogonal methods with patient brain validation, preprint, single lab","pmids":["38313254"],"is_preprint":true},{"year":2023,"finding":"EV-D68 protease 3C cleaves TDP-43 at residue Q327, generating fragments with substantially decreased solubility that promote TDP-43 aggregation and cytotoxicity. EV-D68 protease 2A induces TDP-43 cytoplasmic translocation.","method":"Viral infection assays, protease activity assays, site-specific cleavage mapping (Q327), solubility fractionation, cytotoxicity assays, lopinavir inhibitor experiments","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical cleavage site mapping at specific residue, functional solubility and toxicity assays; single lab","pmids":["37039659"],"is_preprint":false},{"year":2017,"finding":"TDP-43 regulates the biogenesis of a number of miRNAs; TDP-43 knockdown alters miRNA expression profiles, miRNA isoform patterns (isomiRs), and miRNA arm selection. TDP-43 increases miR-500a-3p expression and binds the mature miR-500a-3p sequence. TDP-43 may promote lung cancer cell migration by regulating miR-423-3p.","method":"siRNA-mediated TDP-43 knockdown, small RNA-seq, RNA immunoprecipitation of mature miRNA sequence","journal":"Protein & cell","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single IP method for mature miRNA binding, no functional domain mutagenesis","pmids":["28952053"],"is_preprint":false},{"year":2019,"finding":"TDP-43 and FUS interactomes were determined in HEK293T cells before and after DNA damage. TDP-43 binds to multiple factors important for DNA repair mechanisms including replication-dependent and -independent pathways, with selected interactions validated by co-immunoprecipitation.","method":"Mass spectrometry interactome profiling, co-immunoprecipitation validation, DNA damage induction in HEK293T cells","journal":"Journal of proteome research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — interactome by MS with limited co-IP validation; single lab, no functional mechanistic follow-up for specific interactions","pmids":["31693373"],"is_preprint":false}],"current_model":"TDP-43 is a nuclear RNA/DNA-binding protein that regulates mRNA splicing (including cryptic exon repression and alternative polyadenylation), mRNA stability, miRNA biogenesis, transcription, and autoregulates its own levels via 3'UTR binding; it undergoes liquid-liquid phase separation governed by its C-terminal low-complexity/prion-like domain and N-terminal oligomerization domain, and this condensation capacity is required for proper RNA regulatory function; RNA binding antagonizes pathological phase transitions, while post-translational modifications including CK1δ-mediated phosphorylation, OGT-mediated O-GlcNAcylation, PIAS4-mediated SUMO2/3-ylation, and acetylation in RRMs each modulate its phase separation, aggregation propensity, and subcellular localization; pathological inclusions have a defined cryo-EM structure (double-spiral fold, residues 282–360) and arise via intra-condensate demixing triggered by oxidative stress and up-concentration in stress granules, with proteolytic cleavage required to expose the amyloid core for prion-like seeding; mitochondrial localization of TDP-43 causes complex I dysfunction by binding ND3/ND6 mRNAs; and HSP70 chaperones maintain TDP-43 liquidity in an ATP-dependent manner to prevent irreversible aggregation."},"narrative":{"mechanistic_narrative":"TDP-43 (TARDBP) is a nuclear RNA/DNA-binding protein that governs post-transcriptional gene regulation through cryptic exon repression, alternative polyadenylation, mRNA stability control, miRNA biogenesis, and autoregulation of its own transcript [PMID:28153034, PMID:38313254, PMID:35495061]. Its regulatory output is cell-type specific: conditional deletion reveals distinct cryptic exon programs in neurons versus myocytes, and stage-dependent requirements in the oligodendrocyte lineage where loss causes missplicing of myelination proteins and OPC death [PMID:28153034, PMID:35311646]. Beyond splicing, TDP-43 represses tau mRNA via UG-rich 3'UTR binding through its C-terminal region, shapes alternative polyadenylation of pluripotency factors such as Sox2 in opposition to paraspeckle-mediated sequestration, and constrains transcription near Alu and LINE repetitive elements, with nuclear depletion driving chromatin decondensation, LINE1 retrotransposition, and dsRNA-triggered PKR innate-immune activation [PMID:28335005, PMID:31047794, PMID:31655156, PMID:31042469, PMID:31229690]. TDP-43 function is mechanistically coupled to liquid-liquid phase separation: its C-terminal low-complexity domain drives homomeric condensation on UG-rich RNA clusters that is required to regulate a subset of transcripts including its own autoregulatory 3'UTR, while RNA binding itself antagonizes the aberrant low-complexity-domain interactions that produce pathological inclusions [PMID:34380047, PMID:35495061, PMID:30826182]. Pathological aggregation proceeds by intra-condensate demixing requiring both up-concentration in stress granules and oxidative stress, via RRM1 unfolding and C-terminal hydrophobic interactions, generating filaments whose buried amyloid core (residues 282–360, a double-spiral fold) must be exposed by proteolytic cleavage to seed prion-like spreading [PMID:40412392, PMID:30826182, PMID:37248338]. This phase behavior is tuned by HSP70/HSP90 chaperones that maintain liquidity in an ATP-dependent manner and by post-translational modifications—CK1δ phosphorylation, OGT O-GlcNAcylation, PIAS4-mediated SUMO2/3-ylation, and RRM acetylation—that modulate aggregation propensity and subcellular localization [PMID:33335017, PMID:36709343, PMID:35112738, PMID:33855783, PMID:39982984]. Mislocalized TDP-43 also accumulates in mitochondria, where it binds ND3/ND6 mRNAs to cause complex I dysfunction and neuronal loss [PMID:27348499]. Disease-relevant insults converge on TDP-43: C9orf72 poly(GR) sequesters it RNA-independently into cytoplasmic inclusions, the Perry-disease DCTN1 G71A mutation drives its cytoplasmic mislocalization, and enteroviral 3C protease cleaves it to promote aggregation [PMID:32878979, PMID:33924373, PMID:37039659].","teleology":[{"year":2016,"claim":"Established a mitochondrial, non-canonical pathogenic activity for TDP-43, showing its damage extends beyond nuclear RNA processing to direct impairment of respiratory machinery.","evidence":"Mitochondrial fractionation, RNA immunoprecipitation, respiratory complex assays, and localization-blocking rescue in transgenic mutant TDP-43 mice","pmids":["27348499"],"confidence":"High","gaps":["Mechanism of TDP-43 mitochondrial import not defined","Relationship between mitochondrial and nuclear loss-of-function pools unresolved"]},{"year":2017,"claim":"Defined TDP-43 as a regulator of mRNA stability and cell-type-specific cryptic splicing, linking its 3'UTR UG-binding to tau suppression and showing its splicing targets diverge across tissues.","evidence":"mRNA stability chase assays, RIP, domain mapping, transgenic mice, and conditional knockouts in neurons and myocytes with RNA-seq","pmids":["28335005","28153034"],"confidence":"High","gaps":["Determinants of cell-type-specific cryptic exon selection unknown","Whether tau regulation contributes to disease phenotype not established"]},{"year":2019,"claim":"Showed RNA binding is protective against pathological phase transitions and that nuclear TDP-43 loss has genome-level consequences—repeat-element derepression, retrotransposition, and innate-immune activation.","evidence":"Optogenetic proteinopathy induction with oligonucleotide rescue, FACS-sorted TDP-43-negative nuclei with ATAC-seq/LINE1 assays, GRO-seq, and astrocyte knockdown with PKR epistasis","pmids":["30826182","31042469","31655156","31229690"],"confidence":"High","gaps":["Causal contribution of retrotransposition and dsRNA-PKR signaling to neurodegeneration not demonstrated in vivo","Threshold of nuclear loss required for chromatin effects unclear"]},{"year":2019,"claim":"Implicated proteostasis and trafficking pathways—endocytosis and the VCP/Cdc48 segregase—in TDP-43 turnover and toxicity.","evidence":"Yeast and Drosophila genetic epistasis, co-IP in patient tissue, and endocytosis modulation assays","pmids":["29233983","31767634"],"confidence":"Medium","gaps":["Direct biochemical link between endocytic machinery and TDP-43 clearance not defined","Cross-species relevance to human neurons untested"]},{"year":2019,"claim":"Mapped a pluripotency-stage RNA-regulatory role through alternative polyadenylation and paraspeckle reciprocity.","evidence":"ESC knockdown/overexpression RNA-seq, APA analysis, miRNA reporters, and mouse embryo phenotyping","pmids":["31047794"],"confidence":"Medium","gaps":["Mechanism by which paraspeckles sequester TDP-43 not structurally defined","Generalizability beyond pluripotency unclear"]},{"year":2020,"claim":"Identified HSP70 chaperones as the ATP-dependent core that maintains TDP-43 condensate liquidity and showed RRM acetylation drives RNA-binding-deficient anisosome formation.","evidence":"Live-cell imaging, cryo-electron tomography, anisosome proteomics, and ATP-depletion experiments in neurons","pmids":["33335017"],"confidence":"High","gaps":["Whether anisosomes are an intermediate to pathological aggregates in disease not established","Acetyltransferase responsible for RRM acetylation not identified"]},{"year":2020,"claim":"Showed a disease-specific driver—C9orf72 poly(GR)—sequesters TDP-43 into cytoplasmic inclusions independent of RNA.","evidence":"GFP-(GR)200 transgenic mice, co-IP, RNase treatment, and ASO rescue","pmids":["32878979"],"confidence":"Medium","gaps":["Direct poly(GR)-TDP-43 binding interface not mapped","Contribution of nucleocytoplasmic transport disruption versus direct sequestration not separated"]},{"year":2021,"claim":"Determined the atomic structure of brain-derived TDP-43 filaments, revealing a disease-specific double-spiral fold distinct from in vitro fibrils.","evidence":"Cryo-EM of TDP-43 aggregates from two ALS-FTLD individuals and two brain regions","pmids":["34880495"],"confidence":"High","gaps":["Pathway from soluble TDP-43 to this fold not reconstituted","Whether the fold differs across TDP-43 proteinopathy subtypes unknown"]},{"year":2021,"claim":"Established that condensation capacity, not merely sequence binding, is required for TDP-43 to regulate a subset of UG-rich transcripts including its own autoregulatory feedback.","evidence":"Graded-condensation CTD variants combined with in vitro phase separation, FRAP, iCLIP, and RNA-seq","pmids":["34380047","35495061"],"confidence":"High","gaps":["Which transcripts strictly require condensation versus binding alone incompletely defined","Link between autoregulatory condensation and disease-causing mutations partially characterized"]},{"year":2021,"claim":"Defined post-translational control of TDP-43 phase behavior and localization through SUMOylation, O-GlcNAcylation, and chaperone interplay with the prion-like domain.","evidence":"Co-IP and K136R mutagenesis with SENP1 manipulation, OGT biochemical assays with Drosophila validation, and polyribosome fractionation in stress models","pmids":["34390468","33855783","34378050"],"confidence":"Medium","gaps":["Interplay/hierarchy among the different PTMs not resolved","Stress-granule recruitment kinetics for each modification incomplete"]},{"year":2022,"claim":"Showed CK1δ phosphorylation reduces phase separation and aggregation without disrupting RNA function, and that oligodendrocyte-lineage TDP-43 loss causes stage-specific myelination defects.","evidence":"Phosphomimetic in vitro phase separation, kinase and FRAP assays, molecular dynamics simulations, and stage-specific conditional Tardbp deletion with EM","pmids":["35112738","35311646"],"confidence":"Medium","gaps":["Cellular contexts where CK1δ phosphorylation is protective versus harmful not delineated","Upstream regulation of CK1δ activity on TDP-43 unclear"]},{"year":2023,"claim":"Dissected distinct aggregation routes (monomeric aggresome-dependent versus RNA-binding-deficient LLPS-driven) and showed seeding requires proteolytic exposure of the buried amyloid core; also resolved chaperone recognition of helical PLD elements.","evidence":"Structure-based variants in human neurons, recombinant filament seeding assays with brain-derived material, and NMR plus in vitro chaperone reconstitution","pmids":["37431963","37248338","36709343"],"confidence":"High","gaps":["Identity of the physiological protease exposing the amyloid core not established","How co-chaperone selectivity (DNAJ isoforms) is regulated in vivo unknown"]},{"year":2023,"claim":"Identified additional disease-relevant modifiers of TDP-43 localization and aggregation, including the Perry-disease DCTN1 G71A mutation, enteroviral protease cleavage, and proteostasis kinase cascades.","evidence":"Domain-mapping co-IP for DCTN1, viral protease cleavage-site mapping at Q327, and Drosophila/cell kinase-screen epistasis (PTK2-TBK1-SQSTM1; CHMP2B-CK1)","pmids":["33924373","37039659","31690171","34726688"],"confidence":"Medium","gaps":["Direct structural basis of DCTN1-TDP-43 binding not resolved","Whether these modifier pathways operate in human disease tissue not confirmed"]},{"year":2025,"claim":"Resolved the two-hit trigger for pathological aggregation (stress-granule up-concentration plus oxidative stress) and the RNA-antagonized PIAS4 SUMO2/3 pathway that stabilizes RNA-free TDP-43.","evidence":"Optogenetic concentration control, iPS-motor neurons, mouse and patient validation, engineered demixing-resistant variants, and SUMO conjugation assays with RNA-binding mutants","pmids":["40412392","39982984"],"confidence":"Medium","gaps":["Therapeutic feasibility of blocking intra-condensate demixing untested clinically","How SUMO2/3-ylation and oxidative demixing are temporally coordinated unclear"]},{"year":null,"claim":"It remains unresolved how the protective nuclear condensation/RNA-regulatory functions are mechanistically converted into the cytoplasmic prion-like seeding cascade in human disease, and which single intervention point most effectively halts this transition.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified in vivo model linking nuclear loss-of-function to cytoplasmic gain-of-toxicity","Physiological protease, acetyltransferase, and PTM hierarchy controlling the switch not fully identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[4,10,13,16,26,27,30]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[23,9]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[16,28,30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,9,11,16]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[14,25,27]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[2]},{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[4,16,28,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[23,9]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[6,27,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,2,14,18]}],"complexes":["stress granule","paraspeckle","TDP-43 anisosome"],"partners":["HSPA (HSP70)","PIAS4","OGT","CSNK1D","DCTN1","VCP","PTK2","CHMP2B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13148","full_name":"TAR DNA-binding protein 43","aliases":[],"length_aa":414,"mass_kda":44.7,"function":"RNA-binding protein that is involved in various steps of RNA biogenesis and processing (PubMed:23519609). Preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA molecules predominantly localized within long introns and in the 3'UTR of mRNAs (PubMed:23519609, PubMed:24240615, PubMed:24464995). In turn, regulates the splicing of many non-coding and protein-coding RNAs including proteins involved in neuronal survival, as well as mRNAs that encode proteins relevant for neurodegenerative diseases (PubMed:21358640, PubMed:29438978). Plays a role in maintaining mitochondrial homeostasis by regulating the processing of mitochondrial transcripts (PubMed:28794432). Also regulates mRNA stability by recruiting CNOT7/CAF1 deadenylase on mRNA 3'UTR leading to poly(A) tail deadenylation and thus shortening (PubMed:30520513). In response to oxidative insult, associates with stalled ribosomes localized to stress granules (SGs) and contributes to cell survival (PubMed:19765185, PubMed:23398327). Also participates in the normal skeletal muscle formation and regeneration, forming cytoplasmic myo-granules and binding mRNAs that encode sarcomeric proteins (PubMed:30464263). Plays a role in the maintenance of the circadian clock periodicity via stabilization of the CRY1 and CRY2 proteins in a FBXL3-dependent manner (PubMed:27123980). Negatively regulates the expression of CDK6 (PubMed:19760257). Regulates the expression of HDAC6, ATG7 and VCP in a PPIA/CYPA-dependent manner (PubMed:25678563)","subcellular_location":"Nucleus; Cytoplasm; Cytoplasm, Stress granule; Mitochondrion","url":"https://www.uniprot.org/uniprotkb/Q13148/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/TARDBP","classification":"Common Essential","n_dependent_lines":1187,"n_total_lines":1208,"dependency_fraction":0.9826158940397351},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000120948","cell_line_id":"CID000932","localizations":[{"compartment":"nuclear_punctae","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"TARDBP;TDP43","stoichiometry":10.0},{"gene":"PSMD1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID000932","total_profiled":1310},"omim":[{"mim_id":"621078","title":"MYOPATHY, MYOFIBRILLAR, 13, WITH RIMMED VACUOLES; MFM13","url":"https://www.omim.org/entry/621078"},{"mim_id":"619733","title":"INCLUSION BODY MYOPATHY AND BRAIN WHITE MATTER ABNORMALITIES; IBMWMA","url":"https://www.omim.org/entry/619733"},{"mim_id":"619415","title":"TAU TUBULIN KINASE 1; TTBK1","url":"https://www.omim.org/entry/619415"},{"mim_id":"617074","title":"SMITH-MAGENIS SYNDROME CHROMOSOME REGION, CANDIDATE GENE 8; SMCR8","url":"https://www.omim.org/entry/617074"},{"mim_id":"616820","title":"METHENYLTETRAHYDROFOLATE SYNTHETASE DOMAIN-CONTAINING PROTEIN; MTHFSD","url":"https://www.omim.org/entry/616820"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TARDBP"},"hgnc":{"alias_symbol":["TDP-43","ALS10"],"prev_symbol":[]},"alphafold":{"accession":"Q13148","domains":[{"cath_id":"3.30.70.330","chopping":"105-180","consensus_level":"high","plddt":86.1555,"start":105,"end":180},{"cath_id":"3.30.70.330","chopping":"191-258","consensus_level":"high","plddt":81.961,"start":191,"end":258},{"cath_id":"3.10.20","chopping":"3-75","consensus_level":"high","plddt":83.0604,"start":3,"end":75}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13148","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13148-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13148-F1-predicted_aligned_error_v6.png","plddt_mean":65.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TARDBP","jax_strain_url":"https://www.jax.org/strain/search?query=TARDBP"},"sequence":{"accession":"Q13148","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13148.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13148/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13148"}},"corpus_meta":[{"pmid":"30826182","id":"PMC_30826182","title":"RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.","date":"2019","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/30826182","citation_count":423,"is_preprint":false},{"pmid":"27348499","id":"PMC_27348499","title":"The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity.","date":"2016","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27348499","citation_count":344,"is_preprint":false},{"pmid":"32799899","id":"PMC_32799899","title":"The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.","date":"2020","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/32799899","citation_count":332,"is_preprint":false},{"pmid":"27015757","id":"PMC_27015757","title":"Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.","date":"2016","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27015757","citation_count":306,"is_preprint":false},{"pmid":"33177049","id":"PMC_33177049","title":"TDP-43 proteinopathies: a new wave of neurodegenerative diseases.","date":"2020","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/33177049","citation_count":281,"is_preprint":false},{"pmid":"33335017","id":"PMC_33335017","title":"HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells.","date":"2020","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/33335017","citation_count":269,"is_preprint":false},{"pmid":"34930382","id":"PMC_34930382","title":"TDP-43 Pathology in Alzheimer's Disease.","date":"2021","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/34930382","citation_count":268,"is_preprint":false},{"pmid":"34880495","id":"PMC_34880495","title":"Structure of pathological TDP-43 filaments from ALS with FTLD.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34880495","citation_count":254,"is_preprint":false},{"pmid":"33446423","id":"PMC_33446423","title":"FUS and TDP-43 Phases in Health and Disease.","date":"2021","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33446423","citation_count":245,"is_preprint":false},{"pmid":"23559573","id":"PMC_23559573","title":"TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: summary and update.","date":"2013","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/23559573","citation_count":222,"is_preprint":false},{"pmid":"31042469","id":"PMC_31042469","title":"Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons.","date":"2019","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31042469","citation_count":196,"is_preprint":false},{"pmid":"34380047","id":"PMC_34380047","title":"TDP-43 condensation properties specify its RNA-binding and regulatory repertoire.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/34380047","citation_count":187,"is_preprint":false},{"pmid":"26410029","id":"PMC_26410029","title":"Functional Significance of TDP-43 Mutations in Disease.","date":"2015","source":"Advances in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26410029","citation_count":186,"is_preprint":false},{"pmid":"21700347","id":"PMC_21700347","title":"TDP-43 and FUS: a nuclear affair.","date":"2011","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/21700347","citation_count":177,"is_preprint":false},{"pmid":"29486049","id":"PMC_29486049","title":"Pathomechanisms of TDP-43 in neurodegeneration.","date":"2018","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29486049","citation_count":175,"is_preprint":false},{"pmid":"32878979","id":"PMC_32878979","title":"C9orf72 poly(GR) aggregation induces TDP-43 proteinopathy.","date":"2020","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32878979","citation_count":162,"is_preprint":false},{"pmid":"35112738","id":"PMC_35112738","title":"Disease-linked TDP-43 hyperphosphorylation suppresses TDP-43 condensation and aggregation.","date":"2022","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/35112738","citation_count":153,"is_preprint":false},{"pmid":"32866962","id":"PMC_32866962","title":"Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32866962","citation_count":148,"is_preprint":false},{"pmid":"19333444","id":"PMC_19333444","title":"Molecular neuropathology of TDP-43 proteinopathies.","date":"2009","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19333444","citation_count":128,"is_preprint":false},{"pmid":"28380257","id":"PMC_28380257","title":"TDP-43 and FUS en route from the nucleus to the cytoplasm.","date":"2017","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/28380257","citation_count":127,"is_preprint":false},{"pmid":"18684309","id":"PMC_18684309","title":"ALS and FTLD: two faces of TDP-43 proteinopathy.","date":"2008","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18684309","citation_count":113,"is_preprint":false},{"pmid":"31047794","id":"PMC_31047794","title":"Cross-Regulation between TDP-43 and Paraspeckles Promotes Pluripotency-Differentiation Transition.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31047794","citation_count":109,"is_preprint":false},{"pmid":"27693252","id":"PMC_27693252","title":"TDP-43/FUS in motor neuron disease: Complexity and challenges.","date":"2016","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27693252","citation_count":106,"is_preprint":false},{"pmid":"22608070","id":"PMC_22608070","title":"Rodent models of TDP-43: recent advances.","date":"2012","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22608070","citation_count":100,"is_preprint":false},{"pmid":"31132467","id":"PMC_31132467","title":"Cytoplasmic functions of TDP-43 and FUS and their role in ALS.","date":"2019","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31132467","citation_count":95,"is_preprint":false},{"pmid":"26444430","id":"PMC_26444430","title":"Inflammation Induces TDP-43 Mislocalization and Aggregation.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26444430","citation_count":94,"is_preprint":false},{"pmid":"31555895","id":"PMC_31555895","title":"The basis of clinicopathological heterogeneity in TDP-43 proteinopathy.","date":"2019","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/31555895","citation_count":90,"is_preprint":false},{"pmid":"28153034","id":"PMC_28153034","title":"Tdp-43 cryptic exons are highly variable between cell types.","date":"2017","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/28153034","citation_count":90,"is_preprint":false},{"pmid":"19737636","id":"PMC_19737636","title":"The molecular links between TDP-43 dysfunction and neurodegeneration.","date":"2009","source":"Advances in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19737636","citation_count":89,"is_preprint":false},{"pmid":"29233983","id":"PMC_29233983","title":"Endocytosis regulates TDP-43 toxicity and turnover.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29233983","citation_count":82,"is_preprint":false},{"pmid":"35499795","id":"PMC_35499795","title":"The Role of TDP-43 in Neurodegenerative Disease.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/35499795","citation_count":81,"is_preprint":false},{"pmid":"31445085","id":"PMC_31445085","title":"TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.","date":"2019","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/31445085","citation_count":81,"is_preprint":false},{"pmid":"28112502","id":"PMC_28112502","title":"Phase to Phase with TDP-43.","date":"2017","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28112502","citation_count":80,"is_preprint":false},{"pmid":"30742063","id":"PMC_30742063","title":"Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy.","date":"2019","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30742063","citation_count":79,"is_preprint":false},{"pmid":"40412392","id":"PMC_40412392","title":"Intra-condensate demixing of TDP-43 inside stress granules generates pathological aggregates.","date":"2025","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/40412392","citation_count":77,"is_preprint":false},{"pmid":"37431963","id":"PMC_37431963","title":"Loss of TDP-43 oligomerization or RNA binding elicits distinct aggregation patterns.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/37431963","citation_count":72,"is_preprint":false},{"pmid":"37248338","id":"PMC_37248338","title":"Seeding the aggregation of TDP-43 requires post-fibrillization proteolytic cleavage.","date":"2023","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37248338","citation_count":68,"is_preprint":false},{"pmid":"28335005","id":"PMC_28335005","title":"TDP-43 suppresses tau expression via promoting its mRNA instability.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28335005","citation_count":67,"is_preprint":false},{"pmid":"22751173","id":"PMC_22751173","title":"TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43.","date":"2013","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/22751173","citation_count":67,"is_preprint":false},{"pmid":"27920024","id":"PMC_27920024","title":"Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.","date":"2017","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27920024","citation_count":65,"is_preprint":false},{"pmid":"35101542","id":"PMC_35101542","title":"TDP-43 pathology: From noxious assembly to therapeutic removal.","date":"2022","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/35101542","citation_count":65,"is_preprint":false},{"pmid":"34032984","id":"PMC_34032984","title":"Regulation of TDP-43 phosphorylation in aging and disease.","date":"2021","source":"GeroScience","url":"https://pubmed.ncbi.nlm.nih.gov/34032984","citation_count":64,"is_preprint":false},{"pmid":"24256250","id":"PMC_24256250","title":"The role of TDP-43 in the pathogenesis of ALS and FTLD.","date":"2013","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/24256250","citation_count":63,"is_preprint":false},{"pmid":"37150879","id":"PMC_37150879","title":"Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.","date":"2023","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/37150879","citation_count":62,"is_preprint":false},{"pmid":"21777389","id":"PMC_21777389","title":"TDP-43 and FUS/TLS: cellular functions and implications for neurodegeneration.","date":"2011","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21777389","citation_count":59,"is_preprint":false},{"pmid":"18592312","id":"PMC_18592312","title":"TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander.","date":"2008","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/18592312","citation_count":58,"is_preprint":false},{"pmid":"22028183","id":"PMC_22028183","title":"RNA-binding proteins in neurodegenerative disease: TDP-43 and beyond.","date":"2011","source":"Wiley interdisciplinary reviews. RNA","url":"https://pubmed.ncbi.nlm.nih.gov/22028183","citation_count":54,"is_preprint":false},{"pmid":"33832769","id":"PMC_33832769","title":"Connecting TDP-43 Pathology with Neuropathy.","date":"2021","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/33832769","citation_count":50,"is_preprint":false},{"pmid":"28466273","id":"PMC_28466273","title":"TDP-43 and Cytoskeletal Proteins in ALS.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28466273","citation_count":49,"is_preprint":false},{"pmid":"31229690","id":"PMC_31229690","title":"TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes.","date":"2019","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/31229690","citation_count":48,"is_preprint":false},{"pmid":"21863317","id":"PMC_21863317","title":"Progranulin and TDP-43: mechanistic links and future directions.","date":"2011","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/21863317","citation_count":47,"is_preprint":false},{"pmid":"37088818","id":"PMC_37088818","title":"CircTmeff1 Promotes Muscle Atrophy by Interacting with TDP-43 and Encoding A Novel TMEFF1-339aa Protein.","date":"2023","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37088818","citation_count":46,"is_preprint":false},{"pmid":"35495061","id":"PMC_35495061","title":"TDP-43 Oligomerization and Phase Separation Properties Are Necessary for Autoregulation.","date":"2022","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35495061","citation_count":46,"is_preprint":false},{"pmid":"31690171","id":"PMC_31690171","title":"PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/31690171","citation_count":46,"is_preprint":false},{"pmid":"35383280","id":"PMC_35383280","title":"Cell environment shapes TDP-43 function with implications in neuronal and muscle disease.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/35383280","citation_count":45,"is_preprint":false},{"pmid":"27370226","id":"PMC_27370226","title":"TDP-43 regulates endogenous retrovirus-K viral protein accumulation.","date":"2016","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/27370226","citation_count":44,"is_preprint":false},{"pmid":"30399416","id":"PMC_30399416","title":"Biomarkers for diseases with TDP-43 pathology.","date":"2018","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/30399416","citation_count":42,"is_preprint":false},{"pmid":"21681666","id":"PMC_21681666","title":"TDP-43 autoregulation: implications for disease.","date":"2011","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/21681666","citation_count":42,"is_preprint":false},{"pmid":"21115123","id":"PMC_21115123","title":"TDP-43 toxicity in yeast.","date":"2010","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/21115123","citation_count":41,"is_preprint":false},{"pmid":"34390468","id":"PMC_34390468","title":"SUMOylation Regulates TDP-43 Splicing Activity and Nucleocytoplasmic Distribution.","date":"2021","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/34390468","citation_count":41,"is_preprint":false},{"pmid":"18549326","id":"PMC_18549326","title":"TDP-43 in neurodegenerative disorders.","date":"2008","source":"Expert opinion on biological therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18549326","citation_count":41,"is_preprint":false},{"pmid":"34013172","id":"PMC_34013172","title":"Molecular, functional, and pathological aspects of TDP-43 fragmentation.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34013172","citation_count":40,"is_preprint":false},{"pmid":"28952053","id":"PMC_28952053","title":"TDP-43 regulates cancer-associated microRNAs.","date":"2017","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/28952053","citation_count":39,"is_preprint":false},{"pmid":"36293362","id":"PMC_36293362","title":"Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36293362","citation_count":39,"is_preprint":false},{"pmid":"35311646","id":"PMC_35311646","title":"Stage-specific control of oligodendrocyte survival and morphogenesis by TDP-43.","date":"2022","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/35311646","citation_count":39,"is_preprint":false},{"pmid":"29097807","id":"PMC_29097807","title":"TDP-43 accelerates age-dependent degeneration of interneurons.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29097807","citation_count":37,"is_preprint":false},{"pmid":"31693373","id":"PMC_31693373","title":"Changes to the TDP-43 and FUS Interactomes Induced by DNA Damage.","date":"2019","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/31693373","citation_count":37,"is_preprint":false},{"pmid":"28108532","id":"PMC_28108532","title":"TDP-43 Prions.","date":"2018","source":"Cold Spring Harbor perspectives in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28108532","citation_count":35,"is_preprint":false},{"pmid":"33924373","id":"PMC_33924373","title":"DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33924373","citation_count":33,"is_preprint":false},{"pmid":"29142232","id":"PMC_29142232","title":"TDP-43 misexpression causes defects in dendritic growth.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29142232","citation_count":33,"is_preprint":false},{"pmid":"36709343","id":"PMC_36709343","title":"Metamorphism in TDP-43 prion-like domain determines chaperone recognition.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/36709343","citation_count":30,"is_preprint":false},{"pmid":"23500590","id":"PMC_23500590","title":"TDP-43 high throughput screening analyses in neurodegeneration: advantages and pitfalls.","date":"2013","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/23500590","citation_count":30,"is_preprint":false},{"pmid":"36555399","id":"PMC_36555399","title":"TDP-43 Proteinopathy and Tauopathy: Do They Have Pathomechanistic Links?","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36555399","citation_count":29,"is_preprint":false},{"pmid":"38539264","id":"PMC_38539264","title":"HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases.","date":"2024","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/38539264","citation_count":29,"is_preprint":false},{"pmid":"33855783","id":"PMC_33855783","title":"O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33855783","citation_count":29,"is_preprint":false},{"pmid":"30988363","id":"PMC_30988363","title":"18F-Flortaucipir in TDP-43 associated frontotemporal dementia.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30988363","citation_count":28,"is_preprint":false},{"pmid":"31655156","id":"PMC_31655156","title":"TDP-43 regulates transcription at protein-coding genes and Alu retrotransposons.","date":"2019","source":"Biochimica et biophysica acta. Gene regulatory mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/31655156","citation_count":28,"is_preprint":false},{"pmid":"35185458","id":"PMC_35185458","title":"Expanding the TDP-43 Proteinopathy Pathway From Neurons to Muscle: Physiological and Pathophysiological Functions.","date":"2022","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35185458","citation_count":27,"is_preprint":false},{"pmid":"23889603","id":"PMC_23889603","title":"TDP-43 pathology in polyglutamine diseases: with reference to amyotrphic lateral sclerosis.","date":"2013","source":"Neuropathology : official journal of the Japanese Society of Neuropathology","url":"https://pubmed.ncbi.nlm.nih.gov/23889603","citation_count":26,"is_preprint":false},{"pmid":"40252666","id":"PMC_40252666","title":"Amyotrophic lateral sclerosis caused by TARDBP mutations: from genetics to TDP-43 proteinopathy.","date":"2025","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40252666","citation_count":25,"is_preprint":false},{"pmid":"29916022","id":"PMC_29916022","title":"Mechanisms Associated with TDP-43 Neurotoxicity in ALS/FTLD.","date":"2018","source":"Advances in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29916022","citation_count":25,"is_preprint":false},{"pmid":"31767634","id":"PMC_31767634","title":"Cdc48/VCP and Endocytosis Regulate TDP-43 and FUS Toxicity and Turnover.","date":"2020","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31767634","citation_count":25,"is_preprint":false},{"pmid":"34378050","id":"PMC_34378050","title":"Cytoplasmic TDP-43 is involved in cell fate during stress recovery.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34378050","citation_count":24,"is_preprint":false},{"pmid":"34830074","id":"PMC_34830074","title":"Metals in ALS TDP-43 Pathology.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34830074","citation_count":23,"is_preprint":false},{"pmid":"24649927","id":"PMC_24649927","title":"Targeting TDP-43 in neurodegenerative diseases.","date":"2014","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/24649927","citation_count":23,"is_preprint":false},{"pmid":"36158183","id":"PMC_36158183","title":"Functional implication of ubiquitinating and deubiquitinating mechanisms in TDP-43 proteinopathies.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36158183","citation_count":23,"is_preprint":false},{"pmid":"38853250","id":"PMC_38853250","title":"Elevated nuclear TDP-43 induces constitutive exon skipping.","date":"2024","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/38853250","citation_count":22,"is_preprint":false},{"pmid":"31862626","id":"PMC_31862626","title":"Prion-like properties of assembled TDP-43.","date":"2019","source":"Current opinion in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/31862626","citation_count":22,"is_preprint":false},{"pmid":"33353765","id":"PMC_33353765","title":"TDP-43 Puts the STING in ALS.","date":"2020","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/33353765","citation_count":22,"is_preprint":false},{"pmid":"34726688","id":"PMC_34726688","title":"CHMP2B regulates TDP-43 phosphorylation and cytotoxicity independent of autophagy via CK1.","date":"2021","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/34726688","citation_count":22,"is_preprint":false},{"pmid":"39982984","id":"PMC_39982984","title":"SUMO2/3 conjugation of TDP-43 protects against aggregation.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39982984","citation_count":21,"is_preprint":false},{"pmid":"37039659","id":"PMC_37039659","title":"Enterovirus D68 Infection Induces TDP-43 Cleavage, Aggregation, and Neurotoxicity.","date":"2023","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/37039659","citation_count":21,"is_preprint":false},{"pmid":"33282865","id":"PMC_33282865","title":"The Role of HDAC6 in TDP-43-Induced Neurotoxicity and UPS Impairment.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33282865","citation_count":21,"is_preprint":false},{"pmid":"39736783","id":"PMC_39736783","title":"Decoding TDP-43: the molecular chameleon of neurodegenerative diseases.","date":"2024","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/39736783","citation_count":20,"is_preprint":false},{"pmid":"28687523","id":"PMC_28687523","title":"TDP-43 in the spectrum of MND-FTLD pathologies.","date":"2017","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/28687523","citation_count":20,"is_preprint":false},{"pmid":"34759799","id":"PMC_34759799","title":"TDP-43 and ER Stress in Neurodegeneration: Friends or Foes?","date":"2021","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34759799","citation_count":20,"is_preprint":false},{"pmid":"31118120","id":"PMC_31118120","title":"Structural Transition, Function and Dysfunction of TDP-43 in Neurodegenerative Diseases.","date":"2019","source":"Chimia","url":"https://pubmed.ncbi.nlm.nih.gov/31118120","citation_count":20,"is_preprint":false},{"pmid":"40389397","id":"PMC_40389397","title":"Single-cell RNA-sequencing reveals early mitochondrial dysfunction unique to motor neurons shared across FUS- and TARDBP-ALS.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40389397","citation_count":19,"is_preprint":false},{"pmid":"38313254","id":"PMC_38313254","title":"TDP-43 loss induces extensive cryptic polyadenylation in ALS/FTD.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38313254","citation_count":19,"is_preprint":false},{"pmid":"36675095","id":"PMC_36675095","title":"Reviewing the Potential Links between Viral Infections and TDP-43 Proteinopathies.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36675095","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44284,"output_tokens":8584,"usd":0.130806,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18489,"output_tokens":5322,"usd":0.112748,"stage2_stop_reason":"end_turn"},"total_usd":0.243554,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"Cryo-EM structural determination of pathological TDP-43 filaments from ALS with FTLD brain revealed an amyloid-like filament comprising a single protofilament with a double-spiral-shaped fold spanning residues 282-360 in the low-complexity domain, showing no similarity to TDP-43 filaments formed in vitro and lacking classical cross-β amyloid structure.\",\n      \"method\": \"Cryo-electron microscopy of brain-derived TDP-43 aggregates\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution cryo-EM structure from two independent individuals and two brain regions, replicated within the same study\",\n      \"pmids\": [\"34880495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RNA binding antagonizes neurotoxic phase transitions of TDP-43: aberrant interactions between low-complexity domains drive pathological inclusion formation, and this process is antagonized by RNA binding. Pathological inclusions can form outside stress granules. Treatment with oligonucleotides composed of TDP-43 target sequences prevents inclusions and rescues neurotoxicity.\",\n      \"method\": \"Optogenetic induction of TDP-43 proteinopathy in live cells with spatiotemporal control, live-cell imaging, neurotoxicity assays\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (optogenetics, live imaging, oligonucleotide rescue), mechanistically validated in live neurons with functional readout\",\n      \"pmids\": [\"30826182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TDP-43 accumulates in neuronal mitochondria in ALS/FTD. In mitochondria, wild-type and mutant TDP-43 preferentially bind mitochondria-transcribed mRNAs encoding respiratory complex I subunits ND3 and ND6, impairing their expression and causing specific complex I disassembly. Suppression of TDP-43 mitochondrial localization abolishes mitochondrial dysfunction and neuronal loss, and improves phenotypes in transgenic mutant TDP-43 mice.\",\n      \"method\": \"Mitochondrial fractionation, RNA immunoprecipitation, respiratory complex activity assays, transgenic mouse studies with TDP-43 mitochondrial localization signal blocking\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (fractionation, RIP, functional complex assays, in vivo rescue), replicated across cell and mouse models\",\n      \"pmids\": [\"27348499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"HSP70 family chaperones are the primary components of the liquid core of TDP-43 'anisosomes' (intranuclear liquid spherical shells formed by RNA binding-deficient TDP-43). ATP-dependent HSP70 activity maintains the liquidity of both shells and cores. Reduction of ATP levels converts anisosomes to solid aggregates. Acetylation of RNA recognition motifs renders TDP-43 unable to bind RNA, driving anisosomes formation.\",\n      \"method\": \"Live-cell imaging, cryo-electron tomography, mathematical modeling, proteomics (mass spectrometry of anisosomes components), ATP depletion experiments, proteasome inhibition in neurons\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural imaging plus proteomic identification of HSP70 as core component, functional validation with ATP manipulation and mutagenesis\",\n      \"pmids\": [\"33335017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TDP-43 condensation capacity (governed by C-terminal domain) is required for efficient assembly on subsets of RNA-binding regions containing long clusters of UG-rich motifs, promoting 'binding-region condensates' via homomeric CTD interactions, and is necessary for regulation of a subset of bound transcripts including TDP-43 mRNA autoregulation.\",\n      \"method\": \"Series of TDP-43 CTD variants with graded condensation propensity; in vitro phase separation assays; nuclear mobility (FRAP); iCLIP for RNA-binding regions; RNA-seq for transcriptome regulation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution in vitro combined with iCLIP and RNA-seq, multiple CTD variants, orthogonal functional readouts in single study\",\n      \"pmids\": [\"34380047\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Casein kinase 1δ-mediated TDP-43 hyperphosphorylation on C-terminal serine residues reduces TDP-43 phase separation and aggregation, rendering condensates more liquid-like and dynamic. Phosphomimetic mutations do not affect nuclear import or RNA regulatory functions but suppress accumulation in membrane-less organelles. Multi-scale molecular dynamics simulations reveal reduced homotypic interactions through enhanced solvation of phosphomimetic residues.\",\n      \"method\": \"In vitro phase separation assays with phosphomimetic TDP-43 variants; CK1δ kinase assays; FRAP; molecular dynamics simulations; cellular localization and RNA splicing assays\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution of kinase activity, phosphomimetic mutagenesis, molecular simulation, and cellular functional assays in single study\",\n      \"pmids\": [\"35112738\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TDP-43 aggregation requires two concurrent events: up-concentration within stress granules beyond a threshold AND oxidative stress. These collectively trigger intra-condensate demixing via RRM1 domain unfolding (enabling intermolecular disulfide bonds) and increased hydrophobic patch interactions in the C-terminal domain, generating a TDP-43-enriched phase within stress granules that transitions to pathological aggregates. TDP-43 variants resistant to intra-condensate demixing eliminate pathological aggregates.\",\n      \"method\": \"Live-cell imaging, optogenetic concentration control, iPS-motor neurons, disease mouse model validation, patient sample analysis, engineered TDP-43 variants resistant to demixing\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mechanistic validation using engineered variants, multiple model systems including patient samples, and in vitro reconstitution components; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"40412392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TDP-43 oligomerization and RNA binding govern TDP-43 stability, splicing functionality, LLPS, and subcellular localization. Oligomerization is modulated by RNA binding. Under impaired proteasomal activity: monomeric TDP-43 forms cytoplasmic inclusions via aggresome-dependent pathway, while RNA binding-deficient TDP-43 aggregates in the nucleus via LLPS-driven pathway.\",\n      \"method\": \"Structure-based TDP-43 variants in human neurons and cell lines; near-physiological expression; proteasome inhibition; co-immunoprecipitation; FRAP; imaging\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — structure-based mutations, human neurons, near-physiological expression, multiple orthogonal methods dissecting distinct aggregation pathways\",\n      \"pmids\": [\"37431963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Seeding of TDP-43 aggregation requires post-fibrillization proteolytic cleavage to expose the β-sheet-rich amyloid core buried by flanking structured domains in full-length TDP-43 filaments. Only TDP-43 filaments with exposed amyloid core efficiently seeded aggregation of endogenous TDP-43 in cells and enhanced seeding by brain-derived TDP-43 aggregates.\",\n      \"method\": \"Recombinant full-length TDP-43 filament production; structural characterization; proteolytic cleavage assays; cell-based seeding assays with brain-derived aggregates\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of fibrils, structural characterization, functional seeding assays with brain-derived material; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"37248338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss of nuclear TDP-43 is associated with chromatin decondensation around long interspersed nuclear elements (LINEs) and increased LINE1 DNA content. Loss of TDP-43 leads to increased retrotransposition that can be inhibited with antiretroviral drugs.\",\n      \"method\": \"Subcellular fractionation, FACS enrichment of TDP-43-negative nuclei from post-mortem FTD-ALS brain, RNA-seq, ATAC-seq for chromatin accessibility, LINE1 retrotransposition assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary human tissue combined with functional retrotransposition assay and chromatin accessibility profiling; multiple orthogonal methods\",\n      \"pmids\": [\"31042469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TDP-43 suppresses tau expression by promoting mRNA instability through binding to UG repeats in the 3'-UTR of tau mRNA. The C-terminal region of TDP-43 is required for this function. ALS-causing TDP-43 mutations differentially affect tau mRNA instability.\",\n      \"method\": \"mRNA stability assays (actinomycin D chase), RNA immunoprecipitation, TDP-43 truncation mutants, in vivo TDP-43(M337V) transgenic mouse analysis, human brain correlation studies\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — RIP identifying 3'UTR binding, mRNA stability assays, domain mapping, in vivo validation in transgenic mice and human brain; multiple methods across labs\",\n      \"pmids\": [\"28335005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TDP-43 is SUMOylated in the nuclear compartment both covalently (at lysine 136 via SUMO E3 ligase PIAS4, confirmed by SUMO-mutant K136R) and non-covalently in the RRM1 domain at a SUMO-interacting motif (residues 106-110). SUMOylation modifies TDP-43 splicing activity (specifically exon skipping), influences subcellular localization, and regulates recruitment to stress granules after oxidative stress. DeSUMOylation by SENP1 increases cytoplasmic TDP-43 localization.\",\n      \"method\": \"Co-immunoprecipitation of SUMO-TDP-43, site-directed mutagenesis (K136R), SENP1 overexpression, cell-permeable SENP1 peptide TS-1, splicing assays, immunofluorescence\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP and mutagenesis identifying SUMOylation site, functional splicing assay, single lab with multiple methods\",\n      \"pmids\": [\"34390468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"O-GlcNAc transferase (OGT)-mediated O-GlcNAcylation of TDP-43 suppresses TDP-43 aggregation and hyperphosphorylation and promotes TDP-43's mRNA splicing function. O-GlcNAcylation of TDP-43 promotes proper splicing of STMN2 mRNA, required for normal axonal outgrowth and regeneration.\",\n      \"method\": \"Biochemical O-GlcNAcylation assays, OGT inhibition/overexpression, splicing assays, Drosophila motor neuron overexpression with locomotion and lifespan readouts\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro biochemical assay plus in vivo Drosophila validation, multiple functional readouts; single lab\",\n      \"pmids\": [\"33855783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TDP-43 in pluripotent cells represses formation of paraspeckles by enhancing the polyadenylated short isoform of Neat1 lncRNA. TDP-43 promotes pluripotency by regulating alternative polyadenylation of transcripts encoding pluripotency factors including Sox2, partially protecting its 3'UTR from miR-21-mediated degradation. Conversely, paraspeckles sequester TDP-43 from mRNAs to promote exit from pluripotency.\",\n      \"method\": \"RNA-seq, TDP-43 knockdown/overexpression in mouse embryonic stem cells, alternative polyadenylation analysis, miRNA reporter assays, mouse embryo patterning phenotypes\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic experiments (RNA-seq, polyadenylation assays, miRNA reporters, in vivo embryo phenotypes) in single study; single lab\",\n      \"pmids\": [\"31047794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"C9orf72-derived poly(GR) protein promotes aggregation of endogenous TDP-43 by mediating sequestration of full-length TDP-43 in an RNA-independent manner, inducing cytoplasmic TDP-43 inclusion formation. Poly(GR) also causes mislocalization of nucleocytoplasmic transport factors and nuclear pore complex proteins, resulting in aberrant cytoplasmic accumulation of TDP-43.\",\n      \"method\": \"GFP-(GR)200 transgenic mouse model; immunofluorescence; co-immunoprecipitation; antisense oligonucleotide treatment; RNase treatment to confirm RNA-independence\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic mouse model, RNase treatment establishing RNA-independence, ASO rescue; single lab with multiple methods\",\n      \"pmids\": [\"32878979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TDP-43 knockdown in astrocytes causes accumulation of repetitive element transcripts (including endogenous retroviral sequences) and double-stranded RNA (dsRNA), which activates innate immune signaling through protein kinase R (PKR). Inhibition or knockdown of PKR blocks the pro-inflammatory response induced by TDP-43 loss.\",\n      \"method\": \"siRNA knockdown of TDP-43 in primary rat astrocytes, RNA-seq, immunofluorescence, immunoblotting, PKR chemical inhibition and siRNA knockdown\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function KD with defined molecular mechanism (dsRNA-PKR axis), PKR epistasis rescue; single lab\",\n      \"pmids\": [\"31229690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TDP-43 regulates cryptic exon inclusion in a cell-type-specific manner. Conditional deletion of TDP-43 in excitatory neurons or skeletal myocytes revealed that the majority of TDP-43-repressed cryptic exons are cell type-specific, with only some shared across stem cells, neurons, and myocytes.\",\n      \"method\": \"Conditional knockout mouse models (excitatory neurons and skeletal myocytes), RNA-seq identification of cryptic exons\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic deletion with transcriptomics readout; single lab but clean conditional KO\",\n      \"pmids\": [\"28153034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Stage-specific genetic inactivation of Tardbp in oligodendrocyte lineage cells showed that OPCs require TDP-43 for survival (deletion causes cell loss and rapid regeneration), while oligodendrocytes become less sensitive as they mature. TDP-43 loss in oligodendrocytes causes missplicing of key myelination proteins (cryptic exon incorporation) and morphological defects including inappropriate wrapping of neuronal somata and blood vessels.\",\n      \"method\": \"Conditional in vivo Cre-lox deletion at specific oligodendrocyte lineage stages; transcriptional analysis; behavioral phenotyping; electron microscopy\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean stage-specific genetic inactivation with defined cellular and molecular phenotypes; single lab but multiple lineage stages examined\",\n      \"pmids\": [\"35311646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DCTN1 binds TDP-43 through its CAP-Gly-basic supradomain, dynactin domain, and C-terminal region, preferentially via TDP-43's C-terminal region. The Perry disease-linked DCTN1 p.G71A mutation impairs this interaction. Overexpression of DCTN1(G71A), the dynactin-domain fragment, or C-terminal fragment induces cytoplasmic mislocalization and aggregation of TDP-43.\",\n      \"method\": \"Co-immunoprecipitation, truncation mutant mapping, overexpression of disease mutant DCTN1, immunofluorescence for TDP-43 localization\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — reciprocal domain-mapping pulldown and functional mislocalization assay; single lab, multiple truncation constructs\",\n      \"pmids\": [\"33924373\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TDP-43 turnover and toxicity depend in part upon the endocytosis pathway. TDP-43 inhibits endocytosis and co-localizes with endocytic proteins. Impairing endocytosis increases TDP-43 toxicity, aggregation, and protein levels, while enhancing endocytosis reverses these phenotypes. Locomotor dysfunction in a TDP-43 ALS fly model is exacerbated by endocytic impairment and suppressed by enhancement of endocytic function.\",\n      \"method\": \"Yeast genetics, Drosophila ALS model, co-localization with endocytic markers in ALS patient tissue, endocytosis modulation assays, protein level measurements\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in yeast and Drosophila with patient tissue co-localization validation; single lab but multiple model systems\",\n      \"pmids\": [\"29233983\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Cdc48 (VCP in mammals) physically interacts and co-localizes with TDP-43 in ALS patient tissue, and regulates TDP-43 turnover and toxicity together with its cofactor Ubx3 (implicated in endocytic function) in yeast. TDP-43 expression impairs endocytic function.\",\n      \"method\": \"Yeast genetic screen, co-immunoprecipitation in yeast and ALS patient tissue, toxicity and protein turnover assays, endocytic function measurements\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast genetics plus patient tissue co-IP validation; single lab\",\n      \"pmids\": [\"31767634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TARDBP overexpression induces impairment of the ubiquitin proteasome system (UPS). PTK2/FAK is a suppressor of neurotoxicity induced by UPS impairment downstream of TDP-43. PTK2 activation promotes phosphorylation of SQSTM1/p62 at S403 via TBK1, impairing autophagic degradation of poly-ubiquitinated proteins. Non-phosphorylatable SQSTM1(S403A) reduces insoluble poly-ubiquitinated proteins and neurotoxicity caused by TDP-43 overexpression.\",\n      \"method\": \"Kinase inhibitor screen, Drosophila genetic model, site-directed mutagenesis (SQSTM1 S403A), co-immunoprecipitation, proteasome activity assays, TBK1 epistasis\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase screen, pathway epistasis (PTK2-TBK1-SQSTM1), phospho-null mutant rescue in cells and Drosophila; single lab\",\n      \"pmids\": [\"31690171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CHMP2B regulates TDP-43 phosphorylation and toxicity independent of autophagy via CK1. Downregulation of CHMP2B reduces TDP-43 phosphorylation and toxicity in Drosophila and mammalian cells. CHMP2B modulates CK1 protein levels by negatively regulating ubiquitination and proteasome-mediated turnover of CK1.\",\n      \"method\": \"Drosophila genetic screen, siRNA knockdown in mammalian cells, CK1 inhibition, ubiquitination assays, proteasome assays, immunoblotting\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in Drosophila, mechanism dissected in mammalian cells with kinase inhibition and ubiquitination assays; single lab\",\n      \"pmids\": [\"34726688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TDP-43 broadly affects transcription of protein-coding genes and Alu retrotransposons genome-wide. Loss of TDP-43 results in increased transcription activity near repetitive Alu elements within expressed genes, with the highest densities in shorter genes (<30 kb) whose transcription is most affected by TDP-43.\",\n      \"method\": \"GRO-seq (global run-on sequencing), TDP-43 knockdown in HEK293T cells, ChIP for TDP-43 at transcribed regions\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genome-wide nascent transcription assay with TDP-43 KD; single lab, mechanistically informative readout\",\n      \"pmids\": [\"31655156\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HSP70 and HSP90 chaperones promote TDP-43 phase separation, while HSP40 co-chaperones (DNAJA2, DNAJB1, DNAJB4, DNAJC7) show distinct effects on TDP-43 de-mixing. Chaperones and co-chaperones primarily recognize structured helical elements in TDP-43's prion-like domain. Methionine sulfoxidation of the second helical element impairs phase separation, amyloid formation, chaperone recognition, and alters phosphorylation by CK1δ.\",\n      \"method\": \"NMR structural characterization of TDP-43 prion-like domain, in vitro phase separation assays with purified chaperones, methionine sulfoxidation, kinase phosphorylation assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural data with in vitro biochemical reconstitution of chaperone effects; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"36709343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cytoplasmic TDP-43 associates with polyribosomes in an SH-SY5Y cellular stress model and is detected on polyribosomes in FTD brain lysate, supporting a role for cytoplasmic TDP-43 in translational control during stress. Sorbitol-driven cytoplasmic TDP-43 accumulation followed by oxidative stress triggers PARP cleavage and cellular toxicity.\",\n      \"method\": \"Polyribosome fractionation, immunofluorescence, PARP cleavage assays, brain lysate analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — polyribosome fractionation in cells and patient brain tissue with functional toxicity readout; single lab\",\n      \"pmids\": [\"34378050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TDP-43 oligomerization and phase separation properties are both essential for TDP-43 autoregulation (negative feedback via binding to its own 3'UTR). RNA binding to the central autoregulatory 3'UTR sequence induces TDP-43 condensation in cell lysates. ALS-associated mutation M337V disrupts liquid properties of TDP-43-RNA condensates and autoregulatory function, and decreases cellular clearance of TDP-43.\",\n      \"method\": \"Phase separation assays with purified TDP-43 variants, cell lysate condensation assays, autoregulatory reporter assays, FRAP, fluorescence anisotropy binding assays\",\n      \"journal\": \"Frontiers in neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phase separation and binding assays combined with cellular autoregulation reporter; single lab\",\n      \"pmids\": [\"35495061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"During oxidative stress, TDP-43 is SUMO2/3-ylated by the SUMO E3 ligase PIAS4 within stress granules. Inhibition of TDP-43 SUMO2/3-ylation or PIAS4 depletion leads to irreversible TDP-43 aggregation in stress granules. Binding of TDP-43 to UG-rich RNA antagonizes PIAS4-mediated SUMO2/3-ylation, while RNA dissociation promotes it. SUMO2/3-ylation stabilizes cytosolic RNA-free TDP-43 against aggregation.\",\n      \"method\": \"SUMO conjugation assays, PIAS4 knockdown/inhibition, stress granule assembly assays, RNA binding mutants, immunofluorescence, biochemical aggregation assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — identification of specific E3 ligase (PIAS4) with functional consequence, RNA-SUMO antagonism demonstrated; single lab, multiple methods\",\n      \"pmids\": [\"39982984\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TDP-43 loss of function induces cryptic alternative polyadenylation (APA) events including alternative last exons (ALE), 3'UTR extensions, and intronic polyadenylation. TDP-43 can have both repressive and enhancing action on APA. Cryptic 3'UTR extensions in transcription factors (e.g., ELK1, SIX3, TLX1) lead to increased RNA stability, higher cytoplasmic localisation, and increased wild-type protein translation.\",\n      \"method\": \"Custom bioinformatic APA pipeline, RNA-seq and Ribo-seq, TDP-43 depletion in cells, post-mortem ALS/FTD brain RNA-seq validation\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Ribo-seq and RNA-seq orthogonal methods with patient brain validation, preprint, single lab\",\n      \"pmids\": [\"38313254\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"EV-D68 protease 3C cleaves TDP-43 at residue Q327, generating fragments with substantially decreased solubility that promote TDP-43 aggregation and cytotoxicity. EV-D68 protease 2A induces TDP-43 cytoplasmic translocation.\",\n      \"method\": \"Viral infection assays, protease activity assays, site-specific cleavage mapping (Q327), solubility fractionation, cytotoxicity assays, lopinavir inhibitor experiments\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical cleavage site mapping at specific residue, functional solubility and toxicity assays; single lab\",\n      \"pmids\": [\"37039659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TDP-43 regulates the biogenesis of a number of miRNAs; TDP-43 knockdown alters miRNA expression profiles, miRNA isoform patterns (isomiRs), and miRNA arm selection. TDP-43 increases miR-500a-3p expression and binds the mature miR-500a-3p sequence. TDP-43 may promote lung cancer cell migration by regulating miR-423-3p.\",\n      \"method\": \"siRNA-mediated TDP-43 knockdown, small RNA-seq, RNA immunoprecipitation of mature miRNA sequence\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single IP method for mature miRNA binding, no functional domain mutagenesis\",\n      \"pmids\": [\"28952053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TDP-43 and FUS interactomes were determined in HEK293T cells before and after DNA damage. TDP-43 binds to multiple factors important for DNA repair mechanisms including replication-dependent and -independent pathways, with selected interactions validated by co-immunoprecipitation.\",\n      \"method\": \"Mass spectrometry interactome profiling, co-immunoprecipitation validation, DNA damage induction in HEK293T cells\",\n      \"journal\": \"Journal of proteome research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — interactome by MS with limited co-IP validation; single lab, no functional mechanistic follow-up for specific interactions\",\n      \"pmids\": [\"31693373\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TDP-43 is a nuclear RNA/DNA-binding protein that regulates mRNA splicing (including cryptic exon repression and alternative polyadenylation), mRNA stability, miRNA biogenesis, transcription, and autoregulates its own levels via 3'UTR binding; it undergoes liquid-liquid phase separation governed by its C-terminal low-complexity/prion-like domain and N-terminal oligomerization domain, and this condensation capacity is required for proper RNA regulatory function; RNA binding antagonizes pathological phase transitions, while post-translational modifications including CK1δ-mediated phosphorylation, OGT-mediated O-GlcNAcylation, PIAS4-mediated SUMO2/3-ylation, and acetylation in RRMs each modulate its phase separation, aggregation propensity, and subcellular localization; pathological inclusions have a defined cryo-EM structure (double-spiral fold, residues 282–360) and arise via intra-condensate demixing triggered by oxidative stress and up-concentration in stress granules, with proteolytic cleavage required to expose the amyloid core for prion-like seeding; mitochondrial localization of TDP-43 causes complex I dysfunction by binding ND3/ND6 mRNAs; and HSP70 chaperones maintain TDP-43 liquidity in an ATP-dependent manner to prevent irreversible aggregation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TDP-43 (TARDBP) is a nuclear RNA/DNA-binding protein that governs post-transcriptional gene regulation through cryptic exon repression, alternative polyadenylation, mRNA stability control, miRNA biogenesis, and autoregulation of its own transcript [#16, #28, #26]. Its regulatory output is cell-type specific: conditional deletion reveals distinct cryptic exon programs in neurons versus myocytes, and stage-dependent requirements in the oligodendrocyte lineage where loss causes missplicing of myelination proteins and OPC death [#16, #17]. Beyond splicing, TDP-43 represses tau mRNA via UG-rich 3'UTR binding through its C-terminal region, shapes alternative polyadenylation of pluripotency factors such as Sox2 in opposition to paraspeckle-mediated sequestration, and constrains transcription near Alu and LINE repetitive elements, with nuclear depletion driving chromatin decondensation, LINE1 retrotransposition, and dsRNA-triggered PKR innate-immune activation [#10, #13, #23, #9, #15]. TDP-43 function is mechanistically coupled to liquid-liquid phase separation: its C-terminal low-complexity domain drives homomeric condensation on UG-rich RNA clusters that is required to regulate a subset of transcripts including its own autoregulatory 3'UTR, while RNA binding itself antagonizes the aberrant low-complexity-domain interactions that produce pathological inclusions [#4, #26, #1]. Pathological aggregation proceeds by intra-condensate demixing requiring both up-concentration in stress granules and oxidative stress, via RRM1 unfolding and C-terminal hydrophobic interactions, generating filaments whose buried amyloid core (residues 282–360, a double-spiral fold) must be exposed by proteolytic cleavage to seed prion-like spreading [#6, #1, #8]. This phase behavior is tuned by HSP70/HSP90 chaperones that maintain liquidity in an ATP-dependent manner and by post-translational modifications—CK1δ phosphorylation, OGT O-GlcNAcylation, PIAS4-mediated SUMO2/3-ylation, and RRM acetylation—that modulate aggregation propensity and subcellular localization [#3, #24, #5, #12, #27]. Mislocalized TDP-43 also accumulates in mitochondria, where it binds ND3/ND6 mRNAs to cause complex I dysfunction and neuronal loss [#2]. Disease-relevant insults converge on TDP-43: C9orf72 poly(GR) sequesters it RNA-independently into cytoplasmic inclusions, the Perry-disease DCTN1 G71A mutation drives its cytoplasmic mislocalization, and enteroviral 3C protease cleaves it to promote aggregation [#14, #18, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 2016,\n      \"claim\": \"Established a mitochondrial, non-canonical pathogenic activity for TDP-43, showing its damage extends beyond nuclear RNA processing to direct impairment of respiratory machinery.\",\n      \"evidence\": \"Mitochondrial fractionation, RNA immunoprecipitation, respiratory complex assays, and localization-blocking rescue in transgenic mutant TDP-43 mice\",\n      \"pmids\": [\"27348499\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of TDP-43 mitochondrial import not defined\", \"Relationship between mitochondrial and nuclear loss-of-function pools unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined TDP-43 as a regulator of mRNA stability and cell-type-specific cryptic splicing, linking its 3'UTR UG-binding to tau suppression and showing its splicing targets diverge across tissues.\",\n      \"evidence\": \"mRNA stability chase assays, RIP, domain mapping, transgenic mice, and conditional knockouts in neurons and myocytes with RNA-seq\",\n      \"pmids\": [\"28335005\", \"28153034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of cell-type-specific cryptic exon selection unknown\", \"Whether tau regulation contributes to disease phenotype not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed RNA binding is protective against pathological phase transitions and that nuclear TDP-43 loss has genome-level consequences—repeat-element derepression, retrotransposition, and innate-immune activation.\",\n      \"evidence\": \"Optogenetic proteinopathy induction with oligonucleotide rescue, FACS-sorted TDP-43-negative nuclei with ATAC-seq/LINE1 assays, GRO-seq, and astrocyte knockdown with PKR epistasis\",\n      \"pmids\": [\"30826182\", \"31042469\", \"31655156\", \"31229690\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Causal contribution of retrotransposition and dsRNA-PKR signaling to neurodegeneration not demonstrated in vivo\", \"Threshold of nuclear loss required for chromatin effects unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Implicated proteostasis and trafficking pathways—endocytosis and the VCP/Cdc48 segregase—in TDP-43 turnover and toxicity.\",\n      \"evidence\": \"Yeast and Drosophila genetic epistasis, co-IP in patient tissue, and endocytosis modulation assays\",\n      \"pmids\": [\"29233983\", \"31767634\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link between endocytic machinery and TDP-43 clearance not defined\", \"Cross-species relevance to human neurons untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Mapped a pluripotency-stage RNA-regulatory role through alternative polyadenylation and paraspeckle reciprocity.\",\n      \"evidence\": \"ESC knockdown/overexpression RNA-seq, APA analysis, miRNA reporters, and mouse embryo phenotyping\",\n      \"pmids\": [\"31047794\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which paraspeckles sequester TDP-43 not structurally defined\", \"Generalizability beyond pluripotency unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified HSP70 chaperones as the ATP-dependent core that maintains TDP-43 condensate liquidity and showed RRM acetylation drives RNA-binding-deficient anisosome formation.\",\n      \"evidence\": \"Live-cell imaging, cryo-electron tomography, anisosome proteomics, and ATP-depletion experiments in neurons\",\n      \"pmids\": [\"33335017\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether anisosomes are an intermediate to pathological aggregates in disease not established\", \"Acetyltransferase responsible for RRM acetylation not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed a disease-specific driver—C9orf72 poly(GR)—sequesters TDP-43 into cytoplasmic inclusions independent of RNA.\",\n      \"evidence\": \"GFP-(GR)200 transgenic mice, co-IP, RNase treatment, and ASO rescue\",\n      \"pmids\": [\"32878979\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct poly(GR)-TDP-43 binding interface not mapped\", \"Contribution of nucleocytoplasmic transport disruption versus direct sequestration not separated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Determined the atomic structure of brain-derived TDP-43 filaments, revealing a disease-specific double-spiral fold distinct from in vitro fibrils.\",\n      \"evidence\": \"Cryo-EM of TDP-43 aggregates from two ALS-FTLD individuals and two brain regions\",\n      \"pmids\": [\"34880495\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pathway from soluble TDP-43 to this fold not reconstituted\", \"Whether the fold differs across TDP-43 proteinopathy subtypes unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that condensation capacity, not merely sequence binding, is required for TDP-43 to regulate a subset of UG-rich transcripts including its own autoregulatory feedback.\",\n      \"evidence\": \"Graded-condensation CTD variants combined with in vitro phase separation, FRAP, iCLIP, and RNA-seq\",\n      \"pmids\": [\"34380047\", \"35495061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which transcripts strictly require condensation versus binding alone incompletely defined\", \"Link between autoregulatory condensation and disease-causing mutations partially characterized\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined post-translational control of TDP-43 phase behavior and localization through SUMOylation, O-GlcNAcylation, and chaperone interplay with the prion-like domain.\",\n      \"evidence\": \"Co-IP and K136R mutagenesis with SENP1 manipulation, OGT biochemical assays with Drosophila validation, and polyribosome fractionation in stress models\",\n      \"pmids\": [\"34390468\", \"33855783\", \"34378050\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Interplay/hierarchy among the different PTMs not resolved\", \"Stress-granule recruitment kinetics for each modification incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed CK1δ phosphorylation reduces phase separation and aggregation without disrupting RNA function, and that oligodendrocyte-lineage TDP-43 loss causes stage-specific myelination defects.\",\n      \"evidence\": \"Phosphomimetic in vitro phase separation, kinase and FRAP assays, molecular dynamics simulations, and stage-specific conditional Tardbp deletion with EM\",\n      \"pmids\": [\"35112738\", \"35311646\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular contexts where CK1δ phosphorylation is protective versus harmful not delineated\", \"Upstream regulation of CK1δ activity on TDP-43 unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Dissected distinct aggregation routes (monomeric aggresome-dependent versus RNA-binding-deficient LLPS-driven) and showed seeding requires proteolytic exposure of the buried amyloid core; also resolved chaperone recognition of helical PLD elements.\",\n      \"evidence\": \"Structure-based variants in human neurons, recombinant filament seeding assays with brain-derived material, and NMR plus in vitro chaperone reconstitution\",\n      \"pmids\": [\"37431963\", \"37248338\", \"36709343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the physiological protease exposing the amyloid core not established\", \"How co-chaperone selectivity (DNAJ isoforms) is regulated in vivo unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified additional disease-relevant modifiers of TDP-43 localization and aggregation, including the Perry-disease DCTN1 G71A mutation, enteroviral protease cleavage, and proteostasis kinase cascades.\",\n      \"evidence\": \"Domain-mapping co-IP for DCTN1, viral protease cleavage-site mapping at Q327, and Drosophila/cell kinase-screen epistasis (PTK2-TBK1-SQSTM1; CHMP2B-CK1)\",\n      \"pmids\": [\"33924373\", \"37039659\", \"31690171\", \"34726688\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct structural basis of DCTN1-TDP-43 binding not resolved\", \"Whether these modifier pathways operate in human disease tissue not confirmed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Resolved the two-hit trigger for pathological aggregation (stress-granule up-concentration plus oxidative stress) and the RNA-antagonized PIAS4 SUMO2/3 pathway that stabilizes RNA-free TDP-43.\",\n      \"evidence\": \"Optogenetic concentration control, iPS-motor neurons, mouse and patient validation, engineered demixing-resistant variants, and SUMO conjugation assays with RNA-binding mutants\",\n      \"pmids\": [\"40412392\", \"39982984\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Therapeutic feasibility of blocking intra-condensate demixing untested clinically\", \"How SUMO2/3-ylation and oxidative demixing are temporally coordinated unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the protective nuclear condensation/RNA-regulatory functions are mechanistically converted into the cytoplasmic prion-like seeding cascade in human disease, and which single intervention point most effectively halts this transition.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified in vivo model linking nuclear loss-of-function to cytoplasmic gain-of-toxicity\", \"Physiological protease, acetyltransferase, and PTM hierarchy controlling the switch not fully identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [4, 10, 13, 16, 26, 27, 30]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [23, 9]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [16, 28, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 9, 11, 16]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [14, 25, 27]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [4, 16, 28, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [23, 9]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [6, 27, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 2, 14, 18]}\n    ],\n    \"complexes\": [\"stress granule\", \"paraspeckle\", \"TDP-43 anisosome\"],\n    \"partners\": [\"HSPA (HSP70)\", \"PIAS4\", \"OGT\", \"CSNK1D\", \"DCTN1\", \"VCP\", \"PTK2\", \"CHMP2B\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}